Allogene Therapeutics· @AllogeneTx · X·· 2026-04-20Score60
Reading
Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T
CAR-PRISM’s universal MRD negativity happened in a window of healthier T cells and lower burden; solid tumors do not have that window yet.
Body
The Allogene team is at #AACR26! Today, we’re presenting data on allogeneic BCMA/CD70 dual #CART cells as a potential off-the-shelf option for high-risk multiple myeloma after BCMA therapy.
Stop by to learn more about our next-gen approach. #celltherapy #allogeneic #AACR $ALLO
Heat 19 · 16 likes · 1 reply · 2 reposts
Source: Allogene Therapeutics · x.com